Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
TIGIT
Biotech
BeiGene drops TIGIT drug over poor phase 3 lung cancer prospects
BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT antibody.
James Waldron
Apr 3, 2025 8:05am
What were the biggest clinical trial flops of 2024?
Feb 21, 2025 9:00am
Merck discontinues development of 2 late-stage cancer assets
Dec 16, 2024 5:39pm
iTeos drops one of 3 clinical assets from pipeline
Dec 12, 2024 3:10pm
Roche's TIGIT prospect fails another phase 3 lung cancer test
Nov 26, 2024 4:11am
ESMO: iTeos-GSK's TIGIT star shows meaningful improvement
Sep 14, 2024 2:30am
